GLPG (glpg.com) Market Value to Book Value Ratio

Official company branding of Galapagos N.V. (GLPG)

Galapagos NV (GLPG) relies on external contractors for molecule production and research. This chart reflects the asset's price action, where the key indicator is 0.48. The business is currently struggling with customer churn due to the loss of patent protection while awaiting approval for new drugs. Simultaneously, Galapagos NV (GLPG) is implementing a decentralized approach by creating a network for the manufacturing of CAR-T therapies directly within medical centers.

GLPG Galapagos Corp: Market Value to Book Value in the range 07/04/2022 - 05/08/2026
Original product of Galapagos Genomics

A stable liquidity reserve from previous transactions allows Galapagos NV to focus on CAR-T therapy, which directly impacts the extent to which market capitalization exceeds book value. This ratio compares the business's market value with its net assets, enabling investors to determine the degree of company overvaluation or undervaluation relative to actual capital in a real-time assessment.

Main competitors

Market Capitalization to Book Value Ratio HLN (Haleon plc)|KVUE (kenvue.com) - Market Value to Equity Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|ANIP: Market Value to Book Value|MNKD (MannKind Corp.) - Market Value to Book Value Ratio|Amphastar Corp (AMPH) - Market Cap to Net Assets Ratio|PCRX (Pacira BioSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ars-pharma.com (SPRY)|Theravance Biopharma, Inc. (TBPH) - Market Cap to Net Assets Ratio|Market Value to Book Value AQST (Aquestive Therapeutics Inc)|SCPH: Market Value to Book Value Ratio|TECX - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tonix Pharmaceuticals TNXP|SXTC - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Market Value to Book Value|Market Capitalization to Book Value Ratio EXOZ (Invizyne Technologies, Inc.)|Market-to-Book Ratio ORMP|Entera Bio Ltd. (ENTX) - Market Value to Book Value Ratio|Market Value to Book Value ipatherapeutics.com (HYFT)|ABVC (ABVC BioPharma, Inc.) - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Cumberland Pharmaceuticals Inc CPIX|Quantum BioPharma Limited - Market Capitalization to Book Value Ratio|FGEN: Market Capitalization to Book Value Ratio|Telomir Pharmaceuticals (TELO) - Market Value to Book Value Ratio|Rani Therapeutics Holdings, Inc. (RANI) - Market Value to Book Value Ratio|SNYR (Synergy CHC Corp.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio RLYB|LEXX - Market Value to Book Value Ratio|Market Capitalization to Net Assets Pulmatrix Corporation (PULM)|Market Capitalization to Book Value Ratio PTHL (Pheton Holdings)|Market Capitalization to Book Value Ratio Aptorum Group Ltd APM|Market Capitalization to Book Value Ratio LYRA|IBO: Market Value to Equity Ratio|Market Value to Book Value Ratio TNFA|YCBD (cbdMD) - Market-to-Book Ratio|PRFX: Market Value to Book Value Ratio|Market Capitalization to Book Value Auris Medical (CYTO)|Lipella Pharmaceuticals, Inc. (LIPO) - Market Cap to Net Assets Ratio|Market Value to Book Value OPTN (OptiNose Inc)|PIRS - Market Value to Book Value Ratio|PROC - Capitalization to Book Value Ratio|PTPI - Market Cap to Net Assets Ratio|QLI - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio SLRN (ACELYRIN)|TFFP (TFF Pharmaceuticals Inc.) - Market Value to Equity Ratio